Open-label, prospective, randomized, parallel group study investigating a CNI-low dose regimen with Sandimmun Optoral and Certican in comparison to standard immunosuppressive therapy in renal transplant patients with creeping creatinine.

Trial Profile

Open-label, prospective, randomized, parallel group study investigating a CNI-low dose regimen with Sandimmun Optoral and Certican in comparison to standard immunosuppressive therapy in renal transplant patients with creeping creatinine.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 22 Sep 2012

At a glance

  • Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Mycophenolate mofetil; Mycophenolate sodium; Prednisolone
  • Indications Transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 16 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top